Do analysts recommend CNTN or JBIO?

Jade Biosciences has a consensus target price of $47.43, suggesting a potential upside of 194.95%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Jade Biosciences is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jade Biosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89

Which has preferable earnings and valuation, CNTN or JBIO?

Jade Biosciences is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A Jade Biosciences N/A N/A -$127.41M -$2.02 N/A

Is CNTN or JBIO more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% Jade Biosciences N/A -51.34% -47.32%

Do analysts rate EVMN or CNTN?

Evommune currently has a consensus target price of $49.25, suggesting a potential upside of 138.08%. Given Evommune's stronger consensus rating and higher probable upside, analysts clearly believe Evommune is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evommune 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EVMN or CNTN more profitable?

Evommune's return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Hillstream Biopharma N/A -31.50% -24.72%

Do analysts rate CNTN or VOR?

Vor Biopharma has a consensus price target of $42.25, suggesting a potential upside of 199.86%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vor Biopharma 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82

Which has better earnings & valuation, CNTN or VOR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is CNTN or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% Vor Biopharma N/A N/A N/A

Do analysts rate ZVRA or CNTN?

Zevra Therapeutics presently has a consensus target price of $29.29, indicating a potential upside of 125.80%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Zevra Therapeutics is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CNTN or BIOA?

BioAge Labs has a consensus target price of $43.50, indicating a potential upside of 164.44%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts clearly believe BioAge Labs is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAge Labs 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Hillstream Biopharma (CNTN) Competitors

$3.02 +0.07 (+2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$3.04 +0.02 (+0.79%)

As of 07:30 PM Eastern

Compare

CNTN vs. JBIO, EVMN, VOR, ZVRA, and BIOA

Should you buy Hillstream Biopharma stock or one of its competitors? MarketBeat compares Hillstream Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hillstream Biopharma include Jade Biosciences (JBIO), Evommune (EVMN), Vor Biopharma (VOR), Zevra Therapeutics (ZVRA), and BioAge Labs (BIOA). These companies are all part of the "pharmaceutical products" industry.

How does Hillstream Biopharma compare to Jade Biosciences?

Hillstream Biopharma (NASDAQ:CNTN) and Jade Biosciences (NASDAQ:JBIO) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Jade Biosciences had 4 more articles in the media than Hillstream Biopharma. MarketBeat recorded 5 mentions for Jade Biosciences and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.89 beat Jade Biosciences' score of 0.75 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Hillstream Biopharma	Very Positive
Jade Biosciences	Positive

Hillstream Biopharma's return on equity of -31.50% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Jade Biosciences	N/A	-51.34%	-47.32%

Jade Biosciences has a consensus target price of $47.43, suggesting a potential upside of 194.95%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Jade Biosciences is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

1.2% of Hillstream Biopharma shares are held by institutional investors. 6.7% of Hillstream Biopharma shares are held by insiders. Comparatively, 23.1% of Jade Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Jade Biosciences is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Hillstream Biopharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Summary

Jade Biosciences beats Hillstream Biopharma on 7 of the 13 factors compared between the two stocks.

How does Hillstream Biopharma compare to Evommune?

Evommune (NYSE:EVMN) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

In the previous week, Hillstream Biopharma had 1 more articles in the media than Evommune. MarketBeat recorded 1 mentions for Hillstream Biopharma and 0 mentions for Evommune. Hillstream Biopharma's average media sentiment score of 1.89 beat Evommune's score of 1.79 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Evommune	Very Positive
Hillstream Biopharma	Very Positive

Evommune's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Hillstream Biopharma	N/A	-31.50%	-24.72%

Hillstream Biopharma has lower revenue, but higher earnings than Evommune. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	57.32	-$68.87M	-$9.50	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

Evommune currently has a consensus target price of $49.25, suggesting a potential upside of 138.08%. Given Evommune's stronger consensus rating and higher probable upside, analysts clearly believe Evommune is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Hillstream Biopharma shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Evommune beats Hillstream Biopharma on 7 of the 13 factors compared between the two stocks.

How does Hillstream Biopharma compare to Vor Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Vor Biopharma (NASDAQ:VOR) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 6.7% of Hillstream Biopharma shares are held by company insiders. Comparatively, 0.3% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Hillstream Biopharma has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

In the previous week, Vor Biopharma had 3 more articles in the media than Hillstream Biopharma. MarketBeat recorded 4 mentions for Vor Biopharma and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.89 beat Vor Biopharma's score of 0.71 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Hillstream Biopharma	Very Positive
Vor Biopharma	Positive

Vor Biopharma has a consensus price target of $42.25, suggesting a potential upside of 199.86%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Vor Biopharma's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Vor Biopharma	N/A	N/A	N/A

Summary

Vor Biopharma beats Hillstream Biopharma on 9 of the 11 factors compared between the two stocks.

How does Hillstream Biopharma compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Zevra Therapeutics presently has a consensus target price of $29.29, indicating a potential upside of 125.80%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Zevra Therapeutics is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zevra Therapeutics has higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.20	$83.23M	$1.99	6.52
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 6.7% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Zevra Therapeutics had 20 more articles in the media than Hillstream Biopharma. MarketBeat recorded 21 mentions for Zevra Therapeutics and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.89 beat Zevra Therapeutics' score of 0.12 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Hillstream Biopharma	Very Positive

Zevra Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Zevra Therapeutics has a net margin of 101.58% compared to Hillstream Biopharma's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Hillstream Biopharma	N/A	-31.50%	-24.72%

Summary

Zevra Therapeutics beats Hillstream Biopharma on 11 of the 14 factors compared between the two stocks.

How does Hillstream Biopharma compare to BioAge Labs?

Hillstream Biopharma (NASDAQ:CNTN) and BioAge Labs (NASDAQ:BIOA) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Hillstream Biopharma has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
BioAge Labs	$8.99M	81.34	-$80.61M	-$2.40	N/A

Hillstream Biopharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

In the previous week, BioAge Labs had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for BioAge Labs and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.89 beat BioAge Labs' score of 0.27 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Hillstream Biopharma	Very Positive
BioAge Labs	Neutral

BioAge Labs has a consensus target price of $43.50, indicating a potential upside of 164.44%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts clearly believe BioAge Labs is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Hillstream Biopharma has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
BioAge Labs	-871.75%	-29.40%	-27.26%

1.2% of Hillstream Biopharma shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by insiders. Comparatively, 20.8% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Hillstream Biopharma and BioAge Labs tied by winning 7 of the 14 factors compared between the two stocks.

Get Hillstream Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTN vs. The Competition

Export

Metric	Hillstream Biopharma	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$205.92M	$978.11M	$4.31B	$11.99B
Dividend Yield	N/A	4.84%	9.93%	5.62%
P/E Ratio	N/A	1.47	22.13	24.11
Price / Sales	N/A	135.50	205.07	84.01
Price / Cash	N/A	20.06	41.20	54.72
Price / Book	0.28	7.97	28.34	6.82
Net Income	-$35.92M	-$4.69M	$118.48M	$337.52M
7 Day Performance	23.27%	-1.30%	-2.41%	-0.96%
1 Month Performance	-5.33%	4.90%	0.23%	1.68%
1 Year Performance	N/A	89.92%	12.36%	26.88%

Hillstream Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTN Hillstream Biopharma	0.9411 of 5 stars	$3.02 +2.4%	N/A	N/A	$205.92M	N/A	N/A	2
JBIO Jade Biosciences	3.303 of 5 stars	$15.22 +1.6%	$47.43 +211.6%	+116.1%	$739.41M	N/A	N/A	20
EVMN Evommune	2.9342 of 5 stars	$20.50 +1.5%	$49.25 +140.3%	N/A	$727.21M	$13M	N/A	45	Positive News
VOR Vor Biopharma	2.4391 of 5 stars	$13.28 -0.1%	$42.25 +218.1%	N/A	$720.13M	N/A	N/A	140
ZVRA Zevra Therapeutics	4.4213 of 5 stars	$13.66 +13.0%	$27.67 +102.5%	+45.5%	$714.70M	$106.47M	6.86	20	News Coverage Analyst Forecast Options Volume Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTN) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hillstream Biopharma (CNTN) Competitors

CNTN vs. JBIO, EVMN, VOR, ZVRA, and BIOA

How does Hillstream Biopharma compare to Jade Biosciences?

Summary

How does Hillstream Biopharma compare to Evommune?

Summary

How does Hillstream Biopharma compare to Vor Biopharma?

Summary

How does Hillstream Biopharma compare to Zevra Therapeutics?

Summary

How does Hillstream Biopharma compare to BioAge Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hillstream Biopharma (CNTN) Competitors

CNTN vs. JBIO, EVMN, VOR, ZVRA, and BIOA

How does Hillstream Biopharma compare to Jade Biosciences?

Does the media refer more to CNTN or JBIO?

Is CNTN or JBIO more profitable?

Do analysts recommend CNTN or JBIO?

Do insiders & institutionals hold more shares of CNTN or JBIO?

Which has preferable earnings and valuation, CNTN or JBIO?

Which has more volatility & risk, CNTN or JBIO?

Summary

How does Hillstream Biopharma compare to Evommune?

Does the media favor EVMN or CNTN?

Is EVMN or CNTN more profitable?

Which has higher earnings and valuation, EVMN or CNTN?

Do analysts rate EVMN or CNTN?

Do institutionals & insiders hold more shares of EVMN or CNTN?

Summary

How does Hillstream Biopharma compare to Vor Biopharma?

Do insiders & institutionals believe in CNTN or VOR?

Which has more volatility and risk, CNTN or VOR?

Does the media refer more to CNTN or VOR?

Do analysts rate CNTN or VOR?

Which has better earnings & valuation, CNTN or VOR?

Is CNTN or VOR more profitable?

Summary

How does Hillstream Biopharma compare to Zevra Therapeutics?

Do analysts rate ZVRA or CNTN?

Which has stronger earnings and valuation, ZVRA or CNTN?

Do institutionals and insiders have more ownership in ZVRA or CNTN?

Does the media favor ZVRA or CNTN?

Which has more risk & volatility, ZVRA or CNTN?

Is ZVRA or CNTN more profitable?

Summary

How does Hillstream Biopharma compare to BioAge Labs?

Which has higher earnings and valuation, CNTN or BIOA?

Which has more volatility and risk, CNTN or BIOA?

Does the media favor CNTN or BIOA?

Do analysts prefer CNTN or BIOA?

Is CNTN or BIOA more profitable?

Do institutionals & insiders have more ownership in CNTN or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools